The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Subscribe To Our Newsletter & Stay Updated
